Reversible protein phosphorylation mediated by kinases and phosphatases plays an important role in cellular function regulations such as cell proliferation, apoptosis, subcellular translocation, inflammation and metabolism. The human kinase group includes 518 known protein kinases and about 20 lipid kinases. As we know that most of the kinase inhibitors target highly conserved ATP-binding sites, and highly selective drugs are pursued in terms of their superior safety profile compared to lower selectivity inhibitors, where lower selectivity drugs have off-target kinases inhibition, inhibit cancer cell growth by relieving multiple kinase-dependent pathways, and induce toxic side effects in clinic.
The kinase activity evaluation is critical for biochemical research, clinical diagnosis and drug targeted therapy for serious diseases. The study of a rapid, simple, sensitive and specific method for detecting kinase activity has a wide application prospect, and high-throughput screening (HTS) was used widely developing highly selective inhibitors, and so kinase profiling has become an important standard for the kinase inhibitors evaluation.
The ICE Bioscience has developed a kinase profiling platform based on HTRF and ADP-GLO methods to facilitate the development of new drugs, such as CDK kinase panel (16 types) and TK kinase panel (76 types), 60 mini kinase panel, 207 wild-type kinase panel and 310 kinase panel as shown in the appendix below.
Welcome any further discussion on the assay details and validation data.
Keywords: kinase profiling; Off-target effect; High throughput screening;
Pictures:
Figure 1 FDA-approved kinase inhibitors mapped onto the human kinome
References:
1. Attwood Misty M,Fabbro Doriano,Sokolov Aleksandr V et al. Trends in kinase drug discovery: targets, indications and inhibitor design.[J] .Nat Rev Drug Discov, 2021, 20: 839-861.
Validation data:
Appendix:
CDK family kinase panel (16 kinases) |
|||
CDK1/CycA2 |
CDK3/CycE1 |
CDK6/CycD1 |
CDK12/CycK |
CDK1/CycE1 |
CDK4/CycD3 |
CDK6/CycD3 |
CDK13/CycK |
CDK2/CycA2 |
CDK5/p25NCK |
CDK7/CycH/MAT1 |
CDK16/CycY |
CDK2/CycE1 |
CDK5/p35NCK |
CDK9/CycT1 |
CDK18/CycY |
TK kinase panel list |
|||||||
ALK |
EGFR |
EPHA8 |
FGFR3 |
HER2 |
KIT |
RET |
TRKC |
ABL1 |
DDR1 |
EPHB1 |
FGFR4 |
Her4 |
LCK |
RON |
TXK |
ABL2 |
DDR2 |
EPHB2 |
FGR |
IGF1R |
LYNa |
ROS1 |
TYK2 |
ACK |
EPHA1 |
EPHB3 |
FLT1 |
INSR |
LYNb |
SRC |
TYRO3 |
AXL |
EPHA2 |
EPHB4 |
FLT3 |
IRR |
MER |
SRM |
YES |
BMX |
EPHA3 |
FAK |
FLT4 |
ITK |
MET |
SYK |
ZAP70 |
BRK |
EPHA4 |
FER |
FRK |
JAK1 |
MUSK |
TEC |
|
BTK |
EPHA5 |
FES |
FYN [isoform a] |
JAK2 |
PDGFRα |
TIE2 |
|
CSF1R |
EPHA6 |
FGFR1 |
FYN [isoform b] |
JAK3 |
PDGFRβ |
TRKA |
|
CSK |
EPHA7 |
FGFR2 |
HCK |
KDR |
PYK2 |
TRKB |
Mini kinase panel (60 kinases) |
|||
ABL1 |
CK1γ2 |
IGF1R |
PDGFRα |
AKT1 |
CK1γ3 |
IKK-alpha |
PIM1 |
ALK 4 |
CK2a1 |
ITK |
PKACα |
AMPKα1/β1/γ1 |
CLK1 |
JAK3 |
PKCα |
AurB |
DAPK1 |
JNK1 |
PKD2 |
AXL |
DCAMKL2 |
KDR |
PLK1 |
BRAF |
DYRK1B |
LCK |
PLK2 |
BRSK2 |
EGFR |
MAP2K1 |
ROCK1 |
CDK1/CycE1 |
EPHB4 |
MAPKAPK2 |
RSK1 |
CDK18 |
Erk2 |
MET |
SGK |
CDK2/CycE1 |
FGFR1 |
NEK1 |
SRC |
CDK5/p35NCK |
GSK3β |
NEK2 |
SYK |
CHK1 |
HGK |
p38α |
TIE2 |
CHK2 |
北京爱思益普生物科技股份有限公司 商家主页地 址: 北京市经济技术开发区科创十三街18号院16号楼 联系人: 蔡世伟 电 话: 010-67809840,18513687260 传 真: 010-67809840 Email:caisw@ice-biosci.com 相关咨询细胞免疫学检测服务|细胞增殖实验服务|细胞增殖与细胞活性检测 (暂无发布时间 浏览数:2114) 药物筛选服务平台|细胞平台药物筛选服务|细胞功能实验|爱思益普 (暂无发布时间 浏览数:2088) 细胞活性检测服务|细胞流式检测实验服务|2D细胞增殖实验 (暂无发布时间 浏览数:2071) 细胞增殖与毒性检测|细胞功能试验服务|细胞活性检测实验 (暂无发布时间 浏览数:2083) 细胞增殖实验服务|细胞增殖与细胞活性检测|细胞免疫学检测服务 (暂无发布时间 浏览数:2109) 细胞平台药物筛选服务|细胞功能实验|细胞活性检测服务|爱思益普 (暂无发布时间 浏览数:2035) 报告基因检测服务|细胞增殖实验服务|细胞免疫学检测服务 (暂无发布时间 浏览数:2060) 细胞活性检测服务|细胞流式检测|细胞增殖实验服务|细胞筛选平台 (暂无发布时间 浏览数:1684) 体外靶点筛选实验|细胞活性检测服务|细胞增殖与毒性检测 (暂无发布时间 浏览数:1822) 高通量筛选服务平台|2D细胞增殖实验|细胞功能实验|细胞活性检测 (暂无发布时间 浏览数:2056) ADVERTISEMENT
|